MX2020005562A - Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1. - Google Patents
Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1.Info
- Publication number
- MX2020005562A MX2020005562A MX2020005562A MX2020005562A MX2020005562A MX 2020005562 A MX2020005562 A MX 2020005562A MX 2020005562 A MX2020005562 A MX 2020005562A MX 2020005562 A MX2020005562 A MX 2020005562A MX 2020005562 A MX2020005562 A MX 2020005562A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- antibodies
- subject
- detection
- methods
- Prior art date
Links
- 102000008096 B7-H1 Antigen Human genes 0.000 title abstract 4
- 108010074708 B7-H1 Antigen Proteins 0.000 title abstract 4
- 238000001514 detection method Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 238000000684 flow cytometry Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Optics & Photonics (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
La presente solicitud se refiere a anticuerpos anti-PD-L1 y su uso para detectar PD-L1 en una muestra de un sujeto. En algunas modalidades, el sujeto ha sido tratado con un anticuerpo anti-PD-L1 terapéutico y un anti-PD-L1 descrito en la presente no compite por la unión a PD-L1 con el anticuerpo anti-PD-L1 terapéutico. En algunas modalidades, el anticuerpo anti-PD-L1 está unido a un resto detectable, tal como un fluoróforo y el anticuerpo anti-PD-L1 se usa para detectar PD-L1 en un sujeto que usa citometría de flujo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593125P | 2017-11-30 | 2017-11-30 | |
| PCT/US2018/062999 WO2019108755A1 (en) | 2017-11-30 | 2018-11-29 | Anti-pd-l1 antibodies and methods of using the same for detection of pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005562A true MX2020005562A (es) | 2020-08-20 |
Family
ID=64744946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005562A MX2020005562A (es) | 2017-11-30 | 2018-11-29 | Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11292843B2 (es) |
| EP (1) | EP3717517A1 (es) |
| JP (1) | JP7402158B2 (es) |
| KR (1) | KR102769570B1 (es) |
| CN (1) | CN111918876B (es) |
| AU (1) | AU2018375150A1 (es) |
| CA (1) | CA3082442A1 (es) |
| IL (1) | IL274754A (es) |
| MX (1) | MX2020005562A (es) |
| TW (1) | TW201927820A (es) |
| WO (1) | WO2019108755A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220107251A (ko) * | 2020-01-09 | 2022-08-02 | 에프. 호프만-라 로슈 아게 | 새로운 4-1bbl 삼량체-함유 항원 결합 분자 |
| WO2023143478A1 (en) * | 2022-01-27 | 2023-08-03 | Crown Bioscience Inc. | Novel anti-cd4 and anti-pd-l1 bispecific antibodies |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5342606A (en) | 1984-10-18 | 1994-08-30 | Board Of Regents, The University Of Texas System | Polyazamacrocyclic compounds for complexation of metal ions |
| US5316757A (en) | 1984-10-18 | 1994-05-31 | Board Of Regents, The University Of Texas System | Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用 |
| US5739294A (en) | 1991-12-10 | 1998-04-14 | The Dow Chemical Company | Bicyclopol yazamacrocyclophosphonic acid complexes for use as contrast agents |
| US5480990A (en) | 1991-12-10 | 1996-01-02 | The Dow Chemical Company | Bicyclopolyazamacrocyclocarboxylic acid complexes for use as contrast agents |
| US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
| US5462725A (en) | 1993-05-06 | 1995-10-31 | The Dow Chemical Company | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| US5385893A (en) | 1993-05-06 | 1995-01-31 | The Dow Chemical Company | Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5834456A (en) | 1996-02-23 | 1998-11-10 | The Dow Chemical Company | Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| DE60022369T2 (de) | 1999-10-04 | 2006-05-18 | Medicago Inc., Sainte Foy | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| US6372907B1 (en) | 1999-11-03 | 2002-04-16 | Apptera Corporation | Water-soluble rhodamine dye peptide conjugates |
| EP4331604B1 (en) | 2008-12-09 | 2025-03-05 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| WO2016162368A1 (en) * | 2015-04-07 | 2016-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Non-invasive imaging of tumor pd-l1 expression |
| CA3007135A1 (en) | 2016-03-23 | 2017-09-28 | Mabspace Biosciences (Suzhou) Co., Ltd | Novel anti-pd-l1 antibodies |
| CN107298713B (zh) * | 2017-08-15 | 2019-12-06 | 联合益康（北京）生物科技有限公司 | 一种抗pd-l1抗体及应用、制备方法、试剂盒和药物 |
-
2018
- 2018-11-29 AU AU2018375150A patent/AU2018375150A1/en not_active Abandoned
- 2018-11-29 MX MX2020005562A patent/MX2020005562A/es unknown
- 2018-11-29 KR KR1020207017254A patent/KR102769570B1/ko active Active
- 2018-11-29 WO PCT/US2018/062999 patent/WO2019108755A1/en unknown
- 2018-11-29 EP EP18822195.6A patent/EP3717517A1/en active Pending
- 2018-11-29 CA CA3082442A patent/CA3082442A1/en active Pending
- 2018-11-29 CN CN201880076425.7A patent/CN111918876B/zh active Active
- 2018-11-29 JP JP2020528372A patent/JP7402158B2/ja active Active
- 2018-11-30 TW TW107142873A patent/TW201927820A/zh unknown
-
2020
- 2020-05-18 IL IL274754A patent/IL274754A/en unknown
- 2020-05-27 US US16/885,067 patent/US11292843B2/en active Active
-
2022
- 2022-02-16 US US17/673,648 patent/US20230052312A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP7402158B2 (ja) | 2023-12-20 |
| TW201927820A (zh) | 2019-07-16 |
| EP3717517A1 (en) | 2020-10-07 |
| JP2021507685A (ja) | 2021-02-25 |
| US11292843B2 (en) | 2022-04-05 |
| IL274754A (en) | 2020-07-30 |
| CA3082442A1 (en) | 2019-06-06 |
| US20230052312A1 (en) | 2023-02-16 |
| CN111918876B (zh) | 2024-02-02 |
| AU2018375150A1 (en) | 2020-07-09 |
| KR102769570B1 (ko) | 2025-02-19 |
| CN111918876A (zh) | 2020-11-10 |
| KR20200090823A (ko) | 2020-07-29 |
| US20200291119A1 (en) | 2020-09-17 |
| WO2019108755A1 (en) | 2019-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX374652B (es) | Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco. | |
| CL2019001483A1 (es) | Anticuerpos anti-pd-l1 radiomarcados para imágenes de inmuno-pet. | |
| AR115418A1 (es) | ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS | |
| EA202090247A1 (ru) | Антитела против cd166 и их применения | |
| GEP20227419B (en) | Pd-1-binding molecules and methods of use thereof | |
| EA202090634A1 (ru) | Антагонисты tim-3 для лечения и диагностики онкологических заболеваний | |
| MX2020001752A (es) | Anticuerpos anti-cd3 y metodos de uso. | |
| HRP20221284T1 (hr) | Anti-pvrig antitijela i postupci uporabe | |
| EA201792497A1 (ru) | Антитела к gitr для диагностики злокачественной опухоли | |
| MX366275B (es) | Metodos para detectar y medir la agregacion. | |
| CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| MX2018009738A (es) | Anticuerpos monoclonales de proteína ns1 anti-virus del dengue. | |
| BR112015024553A2 (pt) | anticorpo multiespecífico, anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de anticorpo, imunoconjugado, formulação farmacêutica, uso de anticorpo e método de tratamento de indivíduos com distúrbio | |
| JOP20200216A1 (ar) | تجارب للكشف عن التنكس العصبي | |
| BR112014012590A8 (pt) | Anticorpos anti-cd98 e métodos de uso dos mesmos | |
| MX2024005669A (es) | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano. | |
| WO2015051320A3 (en) | Anti-sox10 antibody systems and methods | |
| EA201992027A1 (ru) | Водный состав антитела против pd-l1 | |
| EA201991506A1 (ru) | Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов | |
| PE20220004A1 (es) | Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh | |
| EA201992316A1 (ru) | Композиции и способы для диагностики рака предстательной железы | |
| MX2020005562A (es) | Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1. | |
| EA201891529A1 (ru) | Композиции и способы обнаружения и лечения рака яичников | |
| MX2016007148A (es) | Metodos de ensayo de beta-glucano. | |
| GB2541596A (en) | Method and composition for determining specific antibody responses to species of filovirus |